CareDx Inc CDNA
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
Is it the right time to buy, sell, or hold?
Start a free trial of Morningstar Investor to unlock exclusive ratings and continuous analyst coverage to help you decide if CDNA is a good fit for your portfolio.
News
-
CareDx Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
-
CareDx Appoints John W. Hanna as its New President and Chief Executive Officer
-
CareDx and Collaborators Present Latest Cardiothoracic Advancements at the 2024 International Society for Heart and Lung Transplantation Meeting
-
CareDx Appoints Bryan Riggsbee to Its Board of Directors
-
CareDx Announces Fourth Quarter and Full Year 2023 Financial Results
-
CareDx to Participate in the Raymond James & Associates’ 45th Annual Institutional Investors Conference
-
CareDx to Report Fourth Quarter and Full Year 2023 Financial Results
-
CareDx Showcases Digital Solutions and Pipeline in Cellular Transplant and Therapy Monitoring at the 2024 Tandem Meetings
Trading Information
- Previous Close Price
- $8.23
- Day Range
- $7.96–8.37
- 52-Week Range
- $4.80–12.93
- Bid/Ask
- $7.99 / $9.05
- Market Cap
- $413.19 Mil
- Volume/Avg
- 757,592 / 795,436
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 1.58
- Dividend Yield (Trailing)
- —
- Dividend Yield (Forward)
- —
- Total Yield
- 6.46%
Company Profile
CareDx Inc operates as a precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers. It offers testing services, products, and digital solutions along with the pre-and post-transplant patient journey and is a provider of genomics-based information for transplant patients. The Company’s commercially available testing services consist of AlloSure Kidney, AlloMap Heart, AlloSure Heart, a dd-cfDNA solution for heart transplant patients, and AlloSure Lung, a dd-cfDNA solution for lung transplant patients. Geographically the company generates the majority of its revenue from the United States. The company generates major revenue from the Testing services.
- Sector
- Healthcare
- Industry
- Diagnostics & Research
- Stock Style Box
- Small Value
- Total Number of Employees
- 643
- Website
- https://www.caredx.com
Comparables
Valuation
|
Metric
|
CDNA
|
FTRE
|
VCYT
|
|---|---|---|---|
Price/Earnings (Normalized) | — | 66.99 | 26.38 |
Price/Book Value | 1.62 | 1.90 | 1.40 |
Price/Sales | 1.58 | 1.06 | 4.00 |
Price/Cash Flow | — | 27.20 | 29.88 |
Price/Earnings
CDNA
FTRE
VCYT
Financial Strength
|
Metric
|
CDNA
|
FTRE
|
VCYT
|
|---|---|---|---|
Quick Ratio | 3.67 | 1.52 | 4.19 |
Current Ratio | 4.02 | 1.62 | 4.66 |
Interest Coverage | — | 1.02 | −5,596.07 |
Quick Ratio
CDNA
FTRE
VCYT
Profitability
|
Metric
|
CDNA
|
FTRE
|
VCYT
|
|---|---|---|---|
Return on Assets (Normalized) | −6.76% | 1.15% | 7.85% |
Return on Equity (Normalized) | −9.03% | 2.40% | 8.41% |
Return on Invested Capital (Normalized) | −10.48% | 3.06% | 7.64% |
Return on Assets
CDNA
FTRE
VCYT
Diagnostics & Research Industry Comparables
|
Ticker
|
Name
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|
TMO
| Thermo Fisher Scientific Inc | Vpwxbbtyy | Bygmq | $209.3 Bil | |
DHR
| Danaher Corp | Kvwjdlczp | Zwvjfzm | $185.5 Bil | |
IQV
| IQVIA Holdings Inc | Nfnjdcdy | Vlhqqm | $43.4 Bil | |
IDXX
| IDEXX Laboratories Inc | Ylrlkssnz | Rvvqd | $41.0 Bil | |
A
| Agilent Technologies Inc | Tjxskgjv | Slys | $40.3 Bil | |
MTD
| Mettler-Toledo International Inc | Jsmgrdqt | Rwylbbb | $26.4 Bil | |
ICLR
| Icon PLC | Mlcmyvfg | Zhwqbvh | $25.2 Bil | |
ILMN
| Illumina Inc | Clvcpndf | Lblxvb | $19.6 Bil | |
WAT
| Waters Corp | Xbzlctwm | Sfxhv | $18.0 Bil | |
LH
| Laboratory Corp of America Holdings | Dswbvvcmc | Zjrbbz | $17.5 Bil |